Roche Acquires AI Specialist PathAI in Major Healthcare Deal.

Swiss pharmaceutical giant Roche has announced the acquisition of American artificial intelligence company PathAI as part of its strategy to strengthen AI-powered healthcare and digital pathology solutions.

The deal is valued at $750 million, with additional milestone payments that could increase the total value by up to $300 million.

Through the acquisition, Roche aims to expand its leadership in AI-based diagnostic technologies and accelerate the development of personalized medicine.

PathAI specializes in artificial intelligence systems used in pathology and medical diagnostics. Its AI-powered Image Management System (IMS) helps laboratories improve efficiency, analyze medical images faster, and support clinical decision-making.

Roche stated that combining PathAI’s technology with Roche’s diagnostic expertise will help speed up the development of new therapies, improve laboratory operations, and support the discovery of new biomarkers and advanced diagnostic tools.

The two companies already began collaborating in 2021, with the partnership expanding further in 2024 before the acquisition announcement.

Roche expects the transaction to be finalized during the second half of 2026, pending approval from regulatory and competition authorities.

After completion, PathAI will be integrated into Roche’s diagnostics division, strengthening the company’s position in the growing field of AI-driven healthcare innovation.

The move highlights the increasing importance of artificial intelligence in global healthcare, where pharmaceutical companies are investing heavily in digital diagnostics, precision medicine, and automated laboratory technologies.